- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07733986
Exercise Therapy for Women With ANOCA (ANOCA Exercise)
Exercise Therapy for Women With ANOCA: a Randomised, Controlled Trial
Angina is a feeling of chest pain or discomfort which can happen if there is reduced blood flow to the heart. Patients can experience angina with no obstructive coronary arteries (ANOCA) which is a difficult condition to treat (ie relieve angina) since few randomised, controlled therapy trials have been undertaken for ANOCA. Until now, angina has been mainly studied in men even though women are at least two-fold more likely than men to experience ANOCA.
In 2023, a Scientific Statement from the American Heart Association affirmed that resistance exercise training can improve or maintain muscle mass and strength and confer favourable physiological and clinical effects on cardiovascular disease and risk factors. Resistance exercise has not been assessed in ANOCA and it offers an important opportunity to study non drug alternatives to treatment for women.
This study will use a resistance based exercise programme to investigate if symptoms of ANOCA can be improved in women. It will recruit at least 76 patients (maximum 152 patients) across 13 hospitals in the UK and the Netherlands.
The study will use a randomised wait list control design. This means all participants will be offered the intervention, but the randomisation will decide when they undergo it.
It is part of a platform of trials for women with ANOCA. We are also setting up a drug study called ANOCA Therapy and a cohort study called ANOCA- Diagnosis.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
There is a gap in knowledge on evidence-based therapy for ANOCA. Stratified medicine is a population-level diagnostic approach for identifying endotypes in a heterogenous population of all-comers. An endotype is defined as a subtype of a condition, which must be characterised by a distinct functional or pathophysiological mechanism.
Use of quantitative noninvasive and invasive diagnostic methods, such as magnetic resonance imaging and coronary function tests involving acetylcholine testing, enables more accurate identification and discrimination of causal endotypes of ANOCA. This is especially relevant for women with ANOCA who have historically been under-recognised.
Quantitative diagnostic methods should bring an end to empirical therapy, therapeutic nihilism and sex disparities in ANOCA.
Precision medicine is different. Precision medicine targets the individual (and their endotype) with a mechanism informed therapy. Accordingly, in this Wellcome Leap Visible project, we will employ a stratified medicine diagnostic approach in women with suspected ANOCA undergoing invasive CFTs in multiple hospitals and then employ a precision medicine strategy by offering each woman an endotype-informed therapy option.
Resistance exercise has not been previously investigated in ANOCA and it therefore represents a novel therapeutic option. This lifestyle intervention will increase the range of trial options, maximize patient choice for participation, and facilitate timely delivery of this project. The beneficial effects of resistance exercise on cardiovascular function have recently been endorsed in a Scientific Statement from the American Heart Association and further supported by a systematic review and favourable experience in our recent randomized trial in Long COVID.
In 2023, a Scientific Statement from the American Heart Association affirmed that resistance exercise training can improve or maintain muscle mass and strength and confer favourable physiological and clinical effects on cardiovascular disease and risk factors. In 19 men with coronary artery disease and endothelial dysfunction, indicated by abnormal acetylcholine-induced coronary vasoconstriction, a randomized controlled trial of aerobic exercise training demonstrated improvements in endothelium-dependent vasodilatation both in epicardial coronary vessels and in resistance vessels. The intervention involved an exercise program six times per day for at least 10 minutes. These results were promising but came with major limitations: no women were included in the study and the exercise program is both burdensome and impractical.
Resistance exercise has not been assessed in ANOCA. Inclusion of a non-CTIMP (lifestyle intervention) brings strategic advantages to our ANOCA platform. A non-medicinal intervention provides an accessible therapy option for women of child-bearing age and for those who may prefer not to participate in an investigational drug trial. This non-CTIMP may also become an option for women who withdraw from a CTIMP, or who complete a CTIMP and are willing to continue into a second trial. The basket trial of resistance exercise may include participants who have completed a precision medicine CTIMP who then wish to participate in the resistance exercise trial or vice versa.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Clare Dolan
- Telefonnummer: 0141 314 4328
- E-post: clare.dolan3@nhs.scot
Studer Kontakt Backup
- Navn: PMU Mail box
- Telefonnummer: 0141 314 4328
- E-post: ggc.pmu.research@nhs.scot
Studiesteder
-
-
-
Basildon, Storbritannia
- Basildon University Hospital
-
Bath, Storbritannia
- Royal United Hospital Bath
-
Cambridge, Storbritannia
- Royal Papworth Hospital
-
Glasgow, Storbritannia, G51 4TF
- Queen Elizabeth University Hospital Clinical Research Facility
-
Ta kontakt med:
- Colin Berry
- Telefonnummer: 0141 232 7600
- E-post: Colin.Berry@glasgow.ac.uk
-
Leeds, Storbritannia
- Leeds General Infirmary
-
London, Storbritannia
- Kings College Hospital
-
London, Storbritannia
- Brompton Hospital
-
London, Storbritannia
- Guy and St Thomas Hospital
-
Newcastle upon Tyne, Storbritannia
- Freeman Hospital
-
Ta kontakt med:
- Vijay Kunadian
-
Nottingham, Storbritannia
- Nottingham City Hospital
-
Sunderland, Storbritannia
- Sunderland Royal Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Angina with no obstructive coronary arties (ANOCA)
- Myocardial perfusion reserve or coronary flow reserve recorded within three years
- Seattle Angina Questionnaire frequency score ≤60
- Duke Activity Status Index ≤34
- Female sex
Exclusion Criteria:
- Age <18 years
- Unable to provide informed consent
- - Unable to comply with the protocol
- Pregnancy
- Currently undertaking resistance exercise activities
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Intervention
Allocated to exercise intervention first
|
Participants will undergo daily resistance based exercise for 8 weeks
|
|
Aktiv komparator: Control
Allocated to exercise intervention second
|
Participants will undergo daily resistance based exercise for 8 weeks
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Seattle Angina Questionnaire
Tidsramme: Change from Baseline to Week 9
|
The Seattle Angina Questionnaire a validated 19-item patient-reported survey used to measure coronary artery disease and angina treatment efficacy.
Patients will complete on paper or electronically.
The scores range from 0 to 100, with higher scores indicating less frequent angina, improved function, and better quality of life.
|
Change from Baseline to Week 9
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Myocardial perfusion reserve (MPR)
Tidsramme: Change from baseline to week 9
|
The ratio of maximum blood flow in the heart muscle under stress compared to resting flow
|
Change from baseline to week 9
|
|
Handgrip strength using hand dynamometer
Tidsramme: Change from baseline to week 9
|
Measured in Kgs.
This is used as a proxy for overall body strength with lower measures indicating less strength.
|
Change from baseline to week 9
|
|
Short Physical Performance Battery (SPPB)
Tidsramme: Change from baseline to week 9
|
Used as a proxy for fitness
|
Change from baseline to week 9
|
|
Brief Illness perception Questionnaire (Brief IPQ)
Tidsramme: Change from baseline to week 9
|
A nine-item scale designed to rapidly assess the cognitive and emotional representations of illness.
It consists of 9 items: 8 are scored on a 0-10 scale, and item 9 is an open-ended question assessing perceived causes.
The total score (0-80) is calculated by summing the first 8 items, with items 3, 4, and 7 reverse scored.
Higher scores generally reflect a more threatening perception of the illness
|
Change from baseline to week 9
|
|
Patient Health Questionnaire-4 of (PHQ4)
Tidsramme: Change from Baseline to Week 9
|
An ultra-brief screening tool used to assess core symptoms of anxiety and depression.
Higher scores indicate greater feelings of anxiety and depression.
|
Change from Baseline to Week 9
|
|
Duke Activity Status Index (DASI)
Tidsramme: From Baseline to Week 9
|
A 12-item, self-administered questionnaire used to estimate a patient's functional capacity and peak oxygen uptake.
Scores range from 0 to 58.2, with higher scores indicating better physical fitness and lower risk
|
From Baseline to Week 9
|
|
EQ-5D (EQ-5D-5L)
Tidsramme: Change from Baseline to Week 9
|
The EQ-5D evaluates health across 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). It yields three metrics: a 5-digit health profile string, a weighted index value, and a 0-100 self-rated Visual Analogue Scale (VAS) score. For the 5-digit health profile string higher individual numbers indicate worse health problems. For the weighted index value a score of 1 indicates perfect health, while 0 represents death. For the visual analogue score higher numbers here indicate better health |
Change from Baseline to Week 9
|
|
International Physical Activity Questionnaire (IPAQ)
Tidsramme: Change from Baseline to Week 9
|
Used to obtain comparable estimates of physical activity between populations and countries.
Higher scores indicate greater physical activity.
|
Change from Baseline to Week 9
|
|
Fatigue severity scale questionnaire
Tidsramme: Change from Baseline to Week 9
|
Rates level of fatigue.
9 statements assess how fatigue impacts daily life.
Each statement is rated on a 7-point Likert scale, ranging from 1 (strongly disagree) to 7 (strongly agree).
Higher scores indicate greater fatigue.
|
Change from Baseline to Week 9
|
|
Short Form Post-Exercise Malaise Questionnaire
Tidsramme: Change from Baseline to Week 9
|
measures symptom exacerbation by assessing frequency and severity of symptoms.
Higher scores reflect a stronger indication of post exercise malaise.
|
Change from Baseline to Week 9
|
|
Episodes of care (primary, secondary, physiotherapy, rehabilitation)
Tidsramme: Week 9
|
How many times participants engaged with services
|
Week 9
|
|
Hospitalisation for any reason by electronic health record review (where available) up to 4 months (Visit 3)
Tidsramme: Week 17
|
Review of medical notes to see if the patient has been in hospital
|
Week 17
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Colin Berry, The University of Glasgow
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- GN26CA170
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .